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Abstract: 
Hepatitis C virus (HCV) infection is associated with increased risk of severe liver damage, cirrhosis, 
and hepatocellular carcinoma (HCC). Despite pending highly efficacious HCV treatment, 
assessment of liver damage will remain important for prognostication, treatment decisions, and 
indication for HCC surveillance. The aims of this thesis was to evaluate (i) which patients benefit 
from look-back screening for HCV, (ii) factors impacting on survival in the HCV-associated liver 
transplant setting, (iii) non-invasive diagnostic markers of HCV-associated cirrhosis and (iv) host 
genetic factors impacting on HCV-associated fibrosis.  
 
In paper I, we identified chronic HCV infection in 113 out of 13,573 subjects (0.8%) screened for 
HCV following blood transfusion prior to 1992. The majority of those individuals were eligible for 
therapeutic intervention. Additionally, 73% of the identified subjects were women, often infected 
following transfusions during childbirth. Thus, screening for HCV among recipients of blood 
transfusions prior to 1992 is meaningful.  
 
In paper II we evaluated survival among 84 patients who underwent liver transplantation for HCV- 
related liver disease from 1992 to 2006. We found that portal inflammation and fibrosis in the donor 
liver may deleteriously affect both patient and graft survival. Thus, pre-transplant evaluation of 
donor histopathology may be of value in the selection of donors for transplantation of HCV positive 
individuals, especially among older donors.  
 
In paper III, we created a new model for prediction of liver cirrhosis in a cohort of 278 patients 
comprising age, body mass index (BMI), platelet count, prothrombin-INR and D7-lathosterol. The 
model was validated in an independent set of 83 patients and could confidently predict cirrhosis 
using the novel index, referred to as the Nordic Liver Index (NoLI). 
  
In paper IV, we noted an association between CC carriage at rs12979860 and more pronounced 
liver damage among HCV genotype 3 infected patients in a cohort of 771 patients with HCV 
infection which suggest that IL28B may differentially regulate the course of HCV infection across 
genotypes. 
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